CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $236.14M, lower than 95% of all stocks globally
- PositionPrice-to-book is 0.89×, lower than 95% of its Biotechnology peers (median 2.86×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
236.14MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
-82.59%vs all stocks
Market Capitalization
236.14MUSDvs all stocks (USD)
Enterprise Value
33.50MUSDvs all stocks (USD)
Forward P/E
-2.34xvs Biotechnology peers
Price to Book (MRQ)
0.8887xvs Biotechnology peers
Enterprise to EBITDA
-0.3080xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-21.54%vs Biotechnology peers
Return on Equity (TTM)
-32.34%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-108.84MUSDvs all stocks (USD)
Net Income (TTM)
-97.38MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-75.92MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-45.44MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-88.98MUSDvs all stocks (USD)
Pre-tax Income
-75.27MUSDFY2025 · Dec 31, 2025Net Income
-75.27MUSDFY2025 · Dec 31, 2025EBIT
-88.98MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-88.33MUSDFY2025 · Dec 31, 2025Research & Development
60.26MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
28.72MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
13.29MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-75.27MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-63.14MUSDFY2025 · Dec 31, 2025Free Cash Flow
-63.52MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
59.41MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-75.27MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
647.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.07MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.96MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-417.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.13MUSDFY2025 · Dec 31, 2025Capital Expenditures
-377.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-325.02MUSDFY2025 · Dec 31, 2025Sale of Investments
206.65MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-118.75MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
202.07MUSDFY2025 · Dec 31, 2025Shares Outstanding
45.16MSharesUpdated Sep 28, 2026Float Shares
20.47MSharesUpdated Sep 28, 2026Shares Short
3.97MSharesUpdated Sep 28, 2026Short Ratio
2.67daysvs all stocks
Short % of Shares Outstanding
14.23%vs all stocks
% Held by Insiders
7.88%vs all stocks
% Held by Institutions
99.59%vs all stocks
Total Cash (MRQ)
211.03MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.67USDUpdated Sep 28, 2026Total Debt (MRQ)
8.07MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0304xvs Biotechnology peers
Current Ratio (MRQ)
20.05xvs Biotechnology peers
Book Value per Share (MRQ)
5.88USDUpdated Sep 28, 2026Total Assets
325.95MUSDvs all stocks (USD)
Total Current Assets
241.42MUSDFY2025 · Dec 31, 2025Total Liabilities
19.12MUSDFY2025 · Dec 31, 2025Total Non-current Assets
84.53MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
7.41MUSDFY2025 · Dec 31, 2025Total Current Liabilities
11.71MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
58.45MUSDFY2025 · Dec 31, 2025Other Short-term Investments
177.43MUSDFY2025 · Dec 31, 2025Accounts Payable
769.00KUSDFY2025 · Dec 31, 2025Short-term Debt
1.27MUSDFY2025 · Dec 31, 2025Other Current Liabilities
6.00KUSDFY2025 · Dec 31, 2025Long-term Debt
7.41MUSDFY2025 · Dec 31, 2025Common Stock (Book)
45.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-256.35MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
306.83MUSDvs all stocks (USD)
52-Week Low
4.01USDUpdated Sep 28, 202652-Week High
54.97USDUpdated Sep 28, 202652-Week Change
-82.59%vs all stocks
50-Day MA
20.20USDUpdated Sep 28, 2026200-Day MA
34.90USDUpdated Sep 28, 2026Avg 10-Day Volume
1.94MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.66MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-2.15USDUpdated Sep 28, 2026Other Income / Expense
419.00KUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.89×, lower than 95% of its Biotechnology peers (median 2.86×)Notable
Price-to-book: 0.89Industry median: 2.86Industry P5: 0.98Peers compared: 260
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.59
Altman Z-Score 6.25: safe zoneNotable
Altman Z-Score: 6.25
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $236.14M, lower than 95% of all stocks globallySignificant
Market cap (USD): 236,136,225Global P5: 275,556,405.438
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Fischer Medical Ventures Ltd
Tier 1ProductionApproval-Gated PipelineFlowRule
Immunotech Biopharm Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Terrascend Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Entrada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Shenqi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Niagen Bioscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Lyell Immunopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Curocell Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Seikagaku Corporation
Tier 1ProductionApproval-Gated PipelineRule
Keros Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
SuperX AI Technology Limited
3 interpretationsLow-Leverage Liquidity ConfigurationDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Guangdong Anda Automation Co., Ltd.
3 interpretationsLow-Leverage Liquidity ConfigurationDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
China Reform Culture Holdings Co. Ltd.
3 interpretationsLow-Leverage Liquidity ConfigurationDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated